Latest news with #TandemDiabetes
Yahoo
01-07-2025
- Business
- Yahoo
Tandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025
SAN DIEGO, July 01, 2025--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2025 results after the financial markets close on Wednesday, August 6, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2025 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at in the "Events & Presentations" section. To access the call by phone, please use this link ( and you will be provided with dial-in details, including a personal pin. An archive of the webcast will be available for 30 days following the event on Tandem Diabetes Care's Investor Center website located at in the "Events & Presentations" section. About Tandem Diabetes Care, Inc. Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company's pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit Tandem Diabetes Care, the Tandem logo, Control-IQ+, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. View source version on Contacts Media Contact: 858-366-6900media@ Investor Contact: 858-366-6900IR@ Sign in to access your portfolio
Yahoo
25-06-2025
- Business
- Yahoo
Diabetes stocks rally after RFK comments on HHS campaign
Sarah Karlin-Smith of Pink Sheet reported via X: 'RFK says HHS about to launch one of the biggest campaigns in HHS history to encourage Americans to use wearable health devices (like CGMs). His vision is every American wearing 'wearable' in 4 years.' Shares of companies in the continuous glucose monitoring space moved higher intraday, including Tandem Diabetes (TNDM), DexCom (DXCM), Insulet (PODD), Abbott (ABT) and Medtronic (MDT). Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on TNDM: Disclaimer & DisclosureReport an Issue Cisco upgraded, CoreWeave downgraded: Wall Street's top analyst calls Tandem Diabetes initiated with a Hold at Truist Tandem Diabetes announces agreement with Abbott to develop diabetes solutions Tandem Diabetes Care: Strategic Initiatives and Product Launches Drive Long-Term Growth Potential Balanced Outlook on Tandem Diabetes Care: Growth Opportunities Amid Strategic Challenges Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-06-2025
- Health
- Yahoo
Tandem's t:slim X2 pump now works with Abbott's FreeStyle CGM sensor
Tandem Diabetes Care has announced its Tandem t:slim X2 insulin pump is now compatible with Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor. The early access programme for this integration has already started in the US, with plans to scale the availability in the second half of this year. With its extended 15-day wear duration, the FreeStyle Libre 3 Plus sensor provides minute-by-minute glucose readings that are directly transmitted to the pump. This allows the data to be viewed on the t:slim mobile app, offering users access to their present glucose trends. Powered by the Control-IQ+ technology, the t:slim X2 insulin pump claims to be the newest generation of hybrid closed-loop algorithm of Tandem, which will adjust insulin delivery every five minutes based on predicted glucose levels. The system's AutoBolus feature is designed to calculate and deliver correction boluses, which help manage missed meal boluses. This technology has ease of use and personalisation, and with this new integration, it extends its benefits to a broader range of individuals with diabetes. Notably, the insulin pump allows users to update features remotely using a personal computer, ensuring that the pump remains equipped with the latest technology throughout its warranty time. Tandem Diabetes Care chief medical officer Dr Jordan Pinsker said: 'Diabetes management is not one-size-fits-all, and it is critical for people living with diabetes to be able to personalise their AID systems to fit their unique healthcare and lifestyle needs. 'The American Diabetes Association recommends AID systems as the preferred insulin delivery method in people with type 1 and other types of insulin-deficient diabetes, and this integration with Abbott's latest generation sensor allows even more CGM users to access the life-changing benefits of our Control-IQ+ technology.' In February 2025, the US Food and Drug Administration (FDA) cleared Tandem Diabetes Care's Control-IQ+ technology, making it available for use by individuals aged 18 and above with type 2 diabetes. "Tandem's t:slim X2 pump now works with Abbott's FreeStyle CGM sensor" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
20-06-2025
- Health
- Yahoo
Tandem Diabetes Care Announces t:slim X2™ Insulin Pump Compatibility with Abbott's FreeStyle Libre® 3 Plus Sensor in the United States
Tandem continues to build its technology ecosystem to expand choice and personalization for people living with diabetes SAN DIEGO, June 20, 2025--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company today announced the Tandem t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology now works with Abbott's FreeStyle Libre® 3 Plus continuous glucose monitoring (CGM) sensor. The Company has initiated an early access program in the United States (U.S.), and intends to scale availability in the second half of 2025. "Diabetes management is not one-size-fits-all and it is critical for people living with diabetes to be able to personalize their AID systems to fit their unique healthcare and lifestyle needs," said Dr. Jordan Pinsker, chief medical officer of Tandem Diabetes Care. "The American Diabetes Association recommends AID systems as the preferred insulin delivery method in people with type 1 and other types of insulin-deficient diabetes, and this integration with Abbott's latest generation sensor allows even more CGM users to access the life-changing benefits of our Control-IQ+ technology." The FreeStyle Libre 3 Plus sensor has an extended 15-day wear time, transmitting automatic glucose readings every minute directly to the pump. This data is also available to view on the Tandem t:slim mobile app, providing users with multiple, convenient ways to access their current glucose trend. The t:slim X2 insulin pump is powered by Control-IQ+ technology, the latest generation of Tandem's advanced hybrid closed-loop algorithm, which adjusts insulin every 5 minutes based on predicted glucose values. It's the only system with the unique AutoBolus™ feature that calculates and delivers a correction bolus to help with missed meal boluses.* Control-IQ+ is easy to start, use, and personalize, and this latest integration works with the FreeStyle Libre 3 Plus sensor and extends its benefits to even more people with diabetes. "This is an exciting first step in our strategy to connect Tandem's portfolio of insulin pumps to Abbott's FreeStyle Libre 3 Plus sensors worldwide," said John Sheridan, president and chief executive officer of Tandem Diabetes Care. "We look forward to expanding access to our t:slim X2 users outside of the U.S. beginning later this year." When available, Tandem will email eligible users in the U.S. with more information.† About Tandem Diabetes CareTandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company's pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit Follow Tandem Diabetes Care on X @tandemdiabetes; use #tslimX2 #TandemMobi and # Tandem Diabetes Care on Facebook at Tandem Diabetes Care on LinkedIn at Forward Looking StatementsThis press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, our ability to provide the software update for current t:slim X2 pump users and the t:slim X2 pumps pre-loaded with Freestyle Libre 3 Plus sensor integration software. These statements are subject to numerous risks and uncertainties, including our ability to sustain commercial scale manufacturing of the t:slim X2 pumps pre-loaded with Freestyle Libre 3 Plus sensor integration software, our ability to operate and maintain a system to facilitate online training for existing t:slim X2 pump customers upgrading their existing devices, and the risk that we may encounter other challenges that may delay the availability of the software update for current t:slim X2 pump users or the t:slim X2 pumps pre-loaded with Freestyle Libre 3 Plus sensor integration software. These and other risks are identified and described in greater detail under the "Risk Factors" heading of our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other documents filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Actual results could differ materially from those anticipated or projected in the forward-looking statements. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events, or other factors. Important Safety Information – FreeStyle Libre SystemsProduct for prescription only; for Important Safety Information, please visit Important Safety Information – Tandem Diabetes CareRX ONLY. The t:slim X2 pump with interoperable technology (the pump) and Control-IQ+ technology (Control-IQ+) are intended for single patient use. The pump and Control-IQ+ are indicated for use with NovoLog or Humalog U-100 insulin. t:slim X2 insulin pump: The pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in persons 2 years of age and greater. Control-IQ+ technology: Control-IQ+ technology is intended for use with compatible integrated continuous glucose monitors (iCGM, sold separately) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ+ technology is intended for the management of Type 1 diabetes mellitus in persons 2 years of age and greater and of Type 2 diabetes mellitus in persons 18 years of age and greater. WARNING: Control-IQ+ should not be used in anyone under the age of 2 years old with Type 1 diabetes or under the age of 18 years old with Type 2 diabetes. It should also not be used in patients who require less than a total daily insulin dose of 5 units of insulin per day or who weigh less than 20 pounds (9 kilograms), as those are the required minimum values needed for Control-IQ+ to operate safely. Users of the pump and Control-IQ+ must: use the insulin pump, iCGM, and all other system components in accordance with their respective instructions for use. Failure to follow these instructions for use could result in an over delivery or under delivery of insulin. This can cause hypoglycemia (low BG) or hyperglycemia (high BG) events. Visit for additional important safety information. © 2025 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, the Tandem logo, Control-IQ+, t:slim X2, t:slim, and Tandem Mobi are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. All other third-party marks are the property of their respective owners. * If glucose values are predicted to be above 180 mg/dL (or 10.0 mmol/L), Control-IQ technology calculates a correction bolus using the Personal Profile settings and a target of 110 mg/dL (or 6.1 mmol/L) and delivers 60% of that value. † Future updates for all or some Tandem products may not be developed and may not be offered everywhere and would be subject to applicable regulatory approvals. Software updates are only available to customers who are in warranty at the time they update their pump. Additional training may be required to access certain software updates. Charges may apply. Tandem may discontinue select software and features over time at its discretion. View source version on Contacts Media Contact: 858-366-6900media@ Investor Contact: 858-366-6900IR@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17-06-2025
- Business
- Yahoo
Abbott, Tandem Diabetes Care Partner For Glucose-Ketone Sensor for Diabetes Management
Abbott Laboratories (NYSE:ABT) is one of the best stocks to buy for beginners now. On June 10, Tandem Diabetes Care Inc. (NASDAQ:TNDM) announced a new agreement with Abbott to develop and commercialize integrated diabetes solutions. The collaboration will combine Abbott's future dual glucose-ketone sensor with Tandem's innovative insulin delivery systems, with the aim of providing more comprehensive management options for individuals with diabetes. The Abbott sensor, which is currently under development, will feature combined glucose and ketone sensing technology. The primary goal of the integrated sensor is to help people living with diabetes detect early rises in ketone levels, and thereby enable them to take prompt action and potentially avoid life-threatening diabetic ketoacidosis/DKA. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. The President and CEO of Tandem Diabetes Care, John Sheridan, stated that integrating Tandem's advanced insulin delivery systems with Abbott's future dual glucose-ketone sensor has the potential to empower patients with diabetes to make faster, more informed decisions about their health, which would ultimately lead to improved outcomes. Abbott Laboratories (NYSE:ABT) discovers, develops, manufactures, and sells health care products worldwide. Tandem Diabetes Care Inc. (NASDAQ:TNDM) designs, develops, and commercializes technology solutions for people living with diabetes. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.